Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amicus Therapeutics (FOLD) EPS (Weighted Average and Diluted) (2019 - 2025)

Amicus Therapeutics' EPS (Weighted Average and Diluted) history spans 7 years, with the latest figure at $0.01 for Q4 2025.

  • For the quarter ending Q4 2025, EPS (Weighted Average and Diluted) fell 89.04% year-over-year to $0.01, compared with a TTM value of -$0.09 through Dec 2025, up 50.0%, and an annual FY2025 reading of -$0.09, up 50.0% over the prior year.
  • EPS (Weighted Average and Diluted) for Q4 2025 was $0.01 at Amicus Therapeutics, down from $0.06 in the prior quarter.
  • The five-year high for EPS (Weighted Average and Diluted) was $0.06 in Q3 2025, with the low at -$0.31 in Q4 2021.
  • Average EPS (Weighted Average and Diluted) over 5 years is -$0.11, with a median of -$0.1 recorded in 2023.
  • Biggest YoY gain for EPS (Weighted Average and Diluted) was 400.0% in 2025; the steepest drop was 89.04% in 2025.
  • Tracing FOLD's EPS (Weighted Average and Diluted) over 5 years: stood at -$0.31 in 2021, then surged by 37.01% to -$0.19 in 2022, then skyrocketed by 43.08% to -$0.11 in 2023, then surged by 145.45% to $0.05 in 2024, then tumbled by 89.04% to $0.01 in 2025.
  • Per Business Quant, the three most recent readings for FOLD's EPS (Weighted Average and Diluted) are $0.01 (Q4 2025), $0.06 (Q3 2025), and -$0.08 (Q2 2025).